- Maximize LINZESS
- Leverage strong commercial capabilities
- Advance robust GI pipeline and guanylate cyclase (GC) research
- Prioritize investments in key value drivers
Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.
New bowel drug Trulance will be available for patients later this quarter.
Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate